Purple Biotech (PPBT) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Purple Biotech announced positive results from its Phase 2 study of CM24 for pancreatic cancer, showing significant improvements in survival rates when combined with nivolumab and chemotherapy. The study highlights its potential as a promising treatment option with a 79% reduction in risk of death in certain biomarker-enriched patient groups. Investors may find these results encouraging as the company moves forward with plans for further clinical studies.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘Time to Jump Ship,’ Says Investor About MicroStrategy Stock
- Nvidia and Microsoft: Why This Top Investment Firm Decided to Dump Shares
- Wells Fargo (NYSE:WFC) Departs Philadelphia Sports Arena
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
